Forgoing bridging anticoagulation offered similar results as bridging with heparin to prevent thromboembolism perioperatively in patients with atrial fibrillation who temporarily halted warfarin ...

Only 8.3% of cases of warfarin interruption involved bridge anticoagulation therapy, which was nearly always with a low-molecular-weight heparin, according to the authors.

Should bridging anticoagulation be used? Guidelines suggest warfarin be stopped about five days before a major procedure. 3 Anticoagulation is resumed when the postoperative bleeding risk is ...

Of those who stopped oral anticoagulation, 24% were bridged with short-acting bridging anticoagulation. The majority of patients were bridged with LMWH.

Bridging anticoagulation aims to minimize the period during which patients are not therapeutically anticoagulated, with the intent of minimizing the risk of perioperative thromboembolism ...

Although relatively common, use of “bridging” medication to protect A-fib patients during the interruption of anticoagulation for procedures is associated with a greater risk of adverse events, ...

Many patients receiving an ICD or a pacemaker are already receiving oral anticoagulants. Current guidelines recommend replacement of the oral anticoagulant with the temporary use of heparin as a ...

DÄ international Archive 18/2007 Perioperative Bridging of Oral Anticoagulation Therapy ...

Bridging with a parenteral agent is “rarely, if ever, needed” in NOAC-treated patients because of the short half-lives of the drugs, the authors say, whereas warfarin-treated patients at high ...

Prior guidelines suggest that the risk with bileaflet or tilting disk valves in the aortic position is low enough not to warrant bridging anticoagulation during discontinuation of warfarin prior ...

Current guidelines recommend bridging many of these patients to heparin treatment and stopping anticoagulation therapy in the days leading up to surgery which can put a patient at risk of a stroke.

High-risk patients should be considered for either bridging therapy or continuation of oral anticoagulation.